✦ LIBER ✦

Glial cells and Parkinson’s disease

✍ Scribed by E. C. Hirsch

Book ID: 105745446
Publisher: Springer
Year: 2000
Tongue: English
Weight: 155 KB
Volume: 247
Category: Article
ISSN: 0340-5354
DOI: 10.1007/pl00007762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pathogenic role of glial cells in Parkin

Pathogenic role of glial cells in Parkinson's disease

✍ Peter Teismann; Kim Tieu; Oren Cohen; Dong-Kug Choi; Du Chu Wu; Daniel Marks; Mi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract An erratum for this article appears in the January, 2004 issue of __Movement__ Disorders (Mov Disord 2004;19:119). Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta (SN

Clarification: Pathogenic role of glial

Clarification: Pathogenic role of glial cells in Parkinson's disease

✍ Serge Przedborski 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 26 KB

## Abstract The original article to which this Clarification refers was published in the February 2003 issue of __Movement__ Disorders (Teismann P, Tieu K, Cohen O, Choi DK, Wu dC, Marks D, Vila M, Jackson‐Lewis V, Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 200

Hippocampal neuron and glial cell number

Hippocampal neuron and glial cell numbers in Parkinson's disease—A stereological study

✍ F.C. Joelving; R. Billeskov; J.R. Christensen; M. West; B. Pakkenberg 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

Hippocampal atrophy and neuron loss are early and reproducible findings in Alzheimer's disease, and recent magnetic resonance imaging studies indicate that hippocampal atrophy may also be present in Parkinson's disease (PD). To determine whether or not cell loss occurs in PD, we estimated the total

Long-term neuroprotection and neuroresto

Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

✍ Elisa Garbayo; Eduardo Ansorena; Jose Luis Lanciego; María Jose Blanco-Prieto; M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 678 KB

## Abstract ## Background: Glial cell‐derived neurotrophic factor is a survival factor for dopaminergic neurons and a promising candidate for the treatment of Parkinson's disease. However, the delivery issue of the protein to the brain still remains unsolved. Our aim was to investigate the effect

Glial cell line-derived neurotrophic fac

Glial cell line-derived neurotrophic factor–secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease

✍ Aleksandra Glavaski-Joksimovic; Tamas Virag; Thomas A. Mangatu; Michael McGrogan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive degeneration of nigrostriatal dopaminergic (DA) neurons. The therapeutic potential of glial cell line‐derived neurotrophic factor (GDNF), the most potent neurotrophic factor for DA neurons, has been dem

Activation of the extracellular signal-r

Activation of the extracellular signal-regulated kinases 1 and 2 by glial cell line-derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease

✍ Niklas Lindgren; Rehana K. Leak; Kirsten M. Carlson; Amanda D. Smith; Michael J. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 851 KB

## Abstract Glial cell line‐derived neurotrophic factor (GDNF) has been shown to be neuroprotective in animal models of the dopamine deficiency in Parkinson's disease. To examine the role of the extracellular signal‐regulated kinases 1 and 2 (ERK1/2) in this process, we infused a single dose of GDN